ReviewFrontiers in immunology2026
Hepatitis C virus-associated B-cell non-Hodgkin lymphomas: immune evasion, multistep lymphomagenesis, and candidate biomarkers for risk stratification and disease monitoring.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis C virus (HCV)-associated B-cell non-Hodgkin lymphomas represent a compelling model of virus-driven oncogenesis in which immune evasion and viral persistence sustain chronic antigenic stimulation, B-cell clonal expansion and progressive multistep lymphomagenesis. Methods: This minireview focuses on mechanisms that connect HCV immune escape with B-cell lymphomagenesis, antiviral treatment responses, and emerging biomarkers for risk stratification and disease monitoring. Results: HCV persistence is sustained by extensive viral genetic variability (quasispecies formation) and by interference with innate and adaptive immune responses, including RIG-I/TLR3 pathway inhibition, suppression of interferon signaling, dendritic cell and natural killer cell dysfunction, and T-cell exhaustion. These mechanisms are relevant to lymphomagenesis because they maintain a persistent antigenic and inflammatory niche that supports chronic antigenic stimulation, clonal B-cell expansion, cytokine and chemokine dysregulation (e.g., BAFF/BLyS axis), apoptotic escape, and the progressive accumulation of genetic alterations and chromosomal aberrations. Lymphomagenesis thus emerges as a complex process consistent with a multistep model. Antiviral therapy provides a clinical indicator of this model, in which regression of some indolent HCV-associated lymphomas after viral eradication supports virus dependence, whereas incomplete lymphoproliferative response and the need for immunochemotherapy in aggressive lymphomas indicate partial independence from the viral trigger at advanced stages. Emerging biomarkers, including B-cell activation markers, immune-inflammatory mediators, immunogenetic susceptibility factors, microRNAs, and genomic alterations, show promise for risk stratification, and disease monitoring, but require further validation. Conclusion: Integrating antiviral and antitumor strategies with biomarker-guided patient stratification may improve early cancer diagnosis and treatment prioritization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.